Summary & Overview
HCPCS J1950: Leuprolide Acetate Depot Injection, 3.75 mg
HCPCS Level II code J1950 denotes an injectable depot formulation of leuprolide acetate, billed per 3.75 mg. As a GnRH agonist, leuprolide acetate is used to suppress gonadal hormone production for conditions such as prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. This code captures the drug component for administration in outpatient settings and is significant for specialty drug billing and oncology, urology, and gynecology practice revenue cycles.
Key national payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer-specific coverage nuances, typical site-of-service settings, and commonly reported modifiers but does not provide state-level policy detail.
Readers will find: a concise description of what J1950 represents clinically and operationally; standard billing contexts for depot injections; benchmark reimbursement and utilization considerations; and guidance on documentation and claim submission elements relevant to injectable specialty pharmaceuticals. Data gaps are noted where input information is incomplete. The emphasis is on national policy and billing context rather than clinical treatment recommendations.
Billing Code Overview
HCPCS Level II code J1950 describes an injection of leuprolide acetate provided as a depot suspension, billed per 3.75 mg. This medication is a gonadotropin-releasing hormone (GnRH) agonist commonly used for conditions that require medical suppression of sex hormones, including prostate cancer, certain gynecologic conditions, and precocious puberty.
-
Service type: Injectable pharmaceutical administration
-
Typical site of service: Outpatient clinic, physician office, ambulatory surgery center, or hospital outpatient department where depot injections are administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult assigned female at birth with a diagnosis of endometriosis or symptomatic uterine fibroids who presents to an outpatient gynecology clinic for management of chronic pelvic pain or heavy menstrual bleeding. After evaluation, the clinician recommends medical ovarian suppression with a depot gonadotropin-releasing hormone (GnRH) agonist. The patient is scheduled for an intramuscular injection of leuprolide acetate depot suspension (per J1950 per 3.75 mg) administered by a registered nurse in the clinic. The clinical workflow includes medication order entry, allergy and consent confirmation, verification of dosing interval (typically every 1 month for the 3.75 mg formulation), preparation of the depot suspension per manufacturer instructions, intramuscular administration (often into the gluteal or deltoid muscle depending on dose and patient factors), post-injection observation for immediate adverse reaction (typically 15–30 minutes if first dose or history of reactions), documentation of lot number and site, and scheduling the next dose. Typical sites of service are outpatient office-based gynecology clinics, ambulatory infusion centers that administer depot injections, and occasionally skilled nursing facilities for patients requiring facility-based administration. Common clinical monitoring includes assessment of symptom response, hot flashes, bone mineral density counseling for long-term use, and documentation of menstruation suppression or return of menses.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 |